A new technology using ultralow temperature cryoablation (ULTC) has eliminated clinical ventricular tachycardia (VT) in 94% of patients. The late-breaking science was presented this week during EHRA 2024, a scientific congress of the European Society of Cardiology (ESC).1 which took place April 7-9 in Berlin, Germany.